AGIO logo

AGIO Agios Pharmaceuticals, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$27.60
-1.16 (-4.03%)

Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionall…

Market Cap: $1.65Bwww.agios.com

Price

No data yet.

Social Signal Score

53
5d
—
30d
50
7 mentions
—
60d
55
10 mentions
—
90d
55
10 mentions
—
news: 10

Analyst Ratings

29 analysts
Buyconsensus
Strong Buy 0Buy 22Hold 7Sell 0Strong Sell 0
Avg price target$40.67+47.4%
Low $32Median $35High $55
Current Consensus

Revenue

$55.38M+144.55%
$0.00$29.03M$58.07M$87.10M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-7.06
$-7.23–$-6.90
8 analysts
FY2026
$-5.56
$-6.74–$-5.30
7 analysts
FY2027
$-3.10
$-5.12–$-1.13
9 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Brian Goff
Sector
Healthcare
Industry
Biotechnology
Employees
540
Beta
0.62
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
10.31
www.agios.com